The raw feed
Latest filings
Every transaction from every Form 4, as filed, newest first. Open-market buys (P) and sells (S) become signals; the rest is shown for completeness.
| Date | Company | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +3,464,072 | - | - | 3,510,927 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +1,484,401 | - | - | 4,995,328 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +165,519 | - | - | 5,160,847 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Common Stockindirect: See footnote | +2,066,857 | - | - | 2,094,813 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Series Seed Convertible Stockderivativeindirect: See footnote | -938,979 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Series A Convertible Preferred Stockderivativeindirect: See footnote | -3,547,842 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -1,027,635 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -3,464,072 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See footnote | -1,484,401 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See footnote | -2,066,857 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Beth C Seidenberg director, owner | CConversion Convertible Promissory Notederivativeindirect: See footnote | -165,519 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +3,117,664 | $0.00 | $0 | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +445,320 | $0.00 | $0 | 3,562,984 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +1,125,823 | $0.00 | $0 | 1,125,823 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +742,201 | $0.00 | $0 | 1,868,024 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +195,776 | - | - | 2,203,800 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +3,117,664 | $0.00 | $0 | 3,117,664 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Common Stockindirect: See Footnote | +296,880 | $0.00 | $0 | 3,414,544 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See Footnote | -3,117,664 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -445,320 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See Footnote | -1,125,823 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -742,201 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Series A-2 Convertible Preferred Stockderivativeindirect: See Footnote | -3,117,664 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Series B Convertible Preferred Stockderivativeindirect: See Footnote | -296,880 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 10, 2026 | LTGO Latigo Biotherapeutics, Inc. | Foresite Capital Management V, LLC owner | CConversion Convertible Promissory Notederivativeindirect: See Footnote | -195,776 | - | - | 0 | Aug 10, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Common Stock | +7,420,091 | - | - | 7,420,091 | Aug 10, 2026 |
| Aug 7, 2026 | BRVE Braveheart Bio, Inc. | Jiangsu Hengrui Pharmaceuticals Co., Ltd. owner | CConversion Non-voting Series A preferred stockderivative | -32,500,000 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | CConversion Common Stock | +2,311,870 | - | - | 2,311,870 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | CConversion Common Stock | +821,998 | - | - | 3,133,868 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | CConversion Common Stock | +665,147 | - | - | 3,799,015 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | CConversion Series A Preferred Stockderivative | -21,477,273 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | CConversion Series B Preferred Stockderivative | -7,636,362 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Aug 6, 2026 | ATTO Attovia Therapeutics, Inc. | venBio Global Strategic Fund IV, L.P. owner | CConversion Series C Preferred Stockderivative | -6,179,219 | $0.00 | $0 | 0 | Aug 10, 2026 |
| Jul 14, 2026 | BAFN BayFirst Financial Corp. | Alfred Tate Rogers Jr CEO & President | CConversion Series D Preferred Stockderivativeindirect: ATRJR IRA, LLC | -52 | - | - | 0 | Aug 7, 2026 |
| Jul 14, 2026 | BAFN BayFirst Financial Corp. | Alfred Tate Rogers Jr CEO & President | CConversion Series D Preferred Stockderivativeindirect: ATRJR, LLC | -98 | - | - | 0 | Aug 7, 2026 |
| Jul 14, 2026 | BAFN BayFirst Financial Corp. | Alfred Tate Rogers Jr CEO & President | CConversion Series D Preferred Stockderivativeindirect: BASS COLLECTIVE, LLC | -8 | - | - | 0 | Aug 7, 2026 |
| Jul 14, 2026 | BAFN BayFirst Financial Corp. | Alfred Tate Rogers Jr CEO & President | CConversion Series D Preferred Stockderivativeindirect: ATRJR ROTH, LLC | -242 | - | - | 0 | Aug 7, 2026 |
| Aug 7, 2026 | PUBM PubMatic, Inc. | Rajeev K. Goel CHIEF EXECUTIVE OFFICER | CConversion Class A Common Stock10b5-1 | +211,302 | - | - | 242,994 | Aug 7, 2026 |
| Aug 7, 2026 | PUBM PubMatic, Inc. | Rajeev K. Goel CHIEF EXECUTIVE OFFICER | CConversion Class B Common Stockderivative10b5-1 | -211,302 | $0.00 | $0 | 198,484 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Ordinary Shares | +9,000,000 | $9.00 | $81M | 9,000,000 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Ordinary Shares | +9,000,000 | $9.00 | $81M | 18,000,000 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Ordinary Shares | +9,000,000 | $9.00 | $81M | 27,000,000 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Ordinary Shares | +28,057,500 | $225.00 | $6.3B | 55,057,500 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Series A Preferred Sharesderivative | -1,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Series B Preferred Sharesderivative | -1,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Series C Preferred Sharesderivative | -1,000,000 | $0.00 | $0 | 0 | Aug 7, 2026 |
| Aug 5, 2026 | QUCY Quantum Cyber N.V. | David E. Lazar Chief Executive Officer | CConversion Series D Preferred Sharesderivative | -124,700 | $0.00 | $0 | 875,300 | Aug 7, 2026 |
| Aug 6, 2026 | CDP CORPORATE OFFICE PROPERTIES TRUST | Robert L Denton director | CConversion Common Units-CDPLPderivative | -1,000 | $0.00 | $0 | 139,264 | Aug 7, 2026 |
| Aug 5, 2026 | ZM Zoom Video Communications, Inc. | Eric S. Yuan Chief Executive Officer | CConversion Class A Common Stockindirect: See footnote10b5-1 | +12,100 | $0.00 | $0 | 35,098 | Aug 7, 2026 |
| Aug 6, 2026 | ZM Zoom Video Communications, Inc. | Eric S. Yuan Chief Executive Officer | CConversion Class A Common Stockindirect: See footnote10b5-1 | +12,100 | $0.00 | $0 | 35,098 | Aug 7, 2026 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.